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AbstrACt
Introduction Chronic inflammatory diseases (CIDs) 
(Crohn’s disease, ulcerative colitis, psoriasis, psoriatic 
arthritis, rheumatoid arthritis and multiple sclerosis) are 
diseases of the immune system that have some shared 
genetic and environmental predisposing factors, but 
still few studies have investigated the effects of lifestyle 
on disease risk of several CIDs. The primary aim of this 
prospective cohort study is to investigate the impact of 
fibre, red meat and processed meat on risk of late-onset 
CID, with the perspective that results of this study can 
contribute in supporting future diet recommendations for 
effective personalised prevention.
Methods and analysis The study will use data from 
57 053 persons from the prospective Danish cohort study 
‘Diet, Cancer and Health’ together with National Health 
Registry data. The follow-up period is from December 
1993 to December 2018. Questionnaire data on diet and 
lifestyle were collected at entry to the Diet, Cancer and 
Health study. The outcome CID is defined as having a 
diagnosis of one of the CIDs registered in the National 
Patient Registry or, for multiple sclerosis, in the Danish 
Multiple Sclerosis Registry during follow-up and being 
treated with a drug used for the specific disease. The 
major outcome of the analyses will be to detect variability 
in risk of late onset of any CID and, if power allows, 
disease risk of late onset of each CID diagnosis between 
persons with different fibre and red meat, and processed 
meat intake. The outcome will be adjusted for age, 
sex, body mass index, physical activity, energy, alcohol, 
fermented dairy products, education, smoking status, 
hormone replacement therapy and comorbidity.
Ethics and dissemination The study is approved by the 
Danish Data Protection Agency (2012-58-0018). The core 
study is an open register-based cohort study. The study 
does not need approval from the Ethics committee or 
Institutional Review Board by Danish law. Study findings 
will be disseminated through peer-reviewed journals, 
patient associations and presentations at international 
conferences.
trial registration number NCT03456206; Post-results.
IntroduCtIon 
The chronic inflammatory diseases (CIDs) 
can be considered as systemic diseases which 
primarily affect one organ such as the intes-
tine (inflammatory bowel disease [IBD]: 
Crohn’s disease [CD] and colitis ulcerosa 
[UC]), skin (psoriasis [PsO]), joints (rheu-
matoid arthritis [RA] and psoriatic arthritis 
[PsA]) or the brain (multiple sclerosis [MS]).
The peak of disease onset is in the adult 
phase of life. The diseases have a large impact 
on the patients and their families’ quality of 
life due to lack of causative treatment, and on 
the society due to the absence from work and 
on healthcare economy due to lack of preven-
tative measures.1–7 The CIDs have a high 
strengths and limitations of this study
 ► The linkage to Danish national registers will ensure 
almost complete follow-up of the study population, 
as the Danish registries are considered of high va-
lidity and completeness.
 ► The big sample size will enable a sufficient power 
of the total late-onset chronic inflammatory disease 
(CID) group even when taking loss to emigration and 
competing risk of death into account.
 ► The study includes several CIDs.
 ► Risk of low specificity of the diagnostic codes and 
treatment codes as criteria for identifying late-onset 
CID cases.
 ► Prospective studies including younger age groups 
are necessary to reveal the generalisability of the 
results.
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prevalence, with IBD and MS affecting, respectively, 0.5% 
and 0.1% of the population in the Western world.8–12 
Studies from across the world have reported prevalence 
estimates of RA and PsO ranging from 0.3% to 1.0% and 
0.7% to 3.2%, respectively,2 8 13–15 while the prevalence of 
PsA is estimated as 0.04%–0.25% across countries.14 16 
Furthermore, one-third of patients with RA are diagnosed 
at >60 years of age17 and the incidence of late-onset IBD 
and MS has been reported to increase.18 19
The CIDs have some shared genetic20–24 and environ-
mental (eg, smoking, gut microbiome) predisposing 
factors, and causes of the high incidence and prevalence 
point to such environmental factors.8 25–40 Therefore, 
further research of the associations between potential 
modifiable environmental risk factors and risk of CID is 
important.
Evidence-based research
It has been demonstrated that a high level of red meat 
consumption is a risk factor for the development of inflam-
matory polyarthritis (including RA).39 40 A high-fibre 
intake has been associated with low risk of IBD.27 Further-
more, several studies of the impact of dietary factors 
on MS point towards an impact of meat preservation 
such as smoking or addition of nitrites.41–44 Studies 
have also suggested other lifestyle factors such as phys-
ical activity,45–47 body mass index (BMI),1 47–49 smoking 
status50–56 and other dietary factors such as alcohol,1 57–59 
dairy products38 and glycaemic index60 61 to be associ-
ated with CIDs. Furthermore, studies have shown that 
the interactions among the microbiota, female sexual 
hormones and immunity are associated with the develop-
ment of autoimmune diseases.62
There are many potential mechanisms whereby 
the environment such as diet may affect the immune 
system (figure 1). Recently, we provided the hypothesis 
that intake of high fibre/low red and processed meat 
may protect against CID.61 Figure 1 presents a model, 
proposed in a previous study,8 whereby a diet high in 
meat and low in fibres may impact inflammation.
Aims and hypotheses
Based on previous evidence, we set out to prospectively 
identify dietary factors that have an impact on disease risk 
of late-onset CID.
The primary aim of this prospective cohort study is to 
investigate the impact of fibre, red meat and processed 
meat on disease risk outcomes of late-onset CID in the 
Figure 1 Hypothesis for effects of diet in relation to the development of chronic inflammatory diseases (CIDs). Diet (meat,97 
fibre,97 animal fat,98 n-330 and n-6 polyunsaturated fatty acids, vitamins A99 and D,100 carotenoids,101 smoking, gluten102) 
may affect the immune system103 104 either directly or indirectly via, for example, the activity and composition of the gut 
microbiome.105 106 The effect of low intake of fibre/high intake of red and processed meat is shown at left: in short, low intake 
of fibre (which could otherwise serve as a nutrient for the microbes) may lead to the microbial metabolism of mucus and to 
decrease of the intestinal mucus layer.61 107 108 A high intake of red and processed meat may render the mucus layer penetrable 
to, for example, bacteria by reducing the disulphide bonds in the mucus network.8 105 109 Thus, microbes may reach the 
epithelium8 110 111 and activate the immune system.8 112 113 There is some support for such a mechanism in CIDs,8 including 
findings of; high amounts of sulphate-reducing bacteria in patients with inflammatory bowel disease (IBD)8 111 114; association 
of high-fibre intake with low risk of IBD among 170 776 participants from the prospective Nurses’ Health Study I8 27; and 
association of high intake of red meat and total protein and risk of developing inflammatory polyarthritis in the population-based 
prospective cohort of 25 630 participants from the European Prospective Investigation of Cancer in Norfolk.8 39 40 IEC, intestinal 
epithelial cell; MAMPs, microbe-associated molecular patterns; NFkB, nuclear factor kappa-light-chain-enhancer of activated B 
cells; TLRs, toll-like receptors; TNF, tumor necrosis factor. Figure from Christensen et al8 (copyright 2018 by Vibeke Andersen).
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‘Diet, Cancer and Health’ (DCH) cohort. The overall 
perspectives are that results from this study will be 
contributing in supporting future diet recommendations 
for effective personalised prevention of individuals iden-
tified to be at high risk.
The main hypothesis is that ‘the risk of late-onset CID 
will be significantly lower among those with a high fibre/
low red meat, and processed meat intake compared with 
those with a low fibre/high red meat and processed meat 
intake.’ The hypothesis is illustrated in figure 1.
Based on previous research on a shared aetiology in 
CIDs, we hypothesise that ‘the suggested association 
between high fibre/low red meat, and processed meat 
intake and risk of developing CID is applicable for each 
of the CID diagnoses’.
The secondary aim of this prospective cohort study is 
to investigate whether risk of late-onset CID in the DCH 
cohort is affected by other dietary and lifestyle differences, 
and therefore to adjust for the potential confounders: 
age, sex, BMI, physical activity, energy, alcohol intake, 
intake of fermented dairy products, education after basic 
school, hormone replacement therapy (HRT), smoking 
status and comorbidity.
MEthods And AnAlysEs
design and setting
This study is an observational study using prospective 
registry follow-up data. We will use the Danish cohort 
‘DCH’, and the follow-up period will be from the date of 
entry in the DCH cohort (between December 1993 and 
May 1997) until December 2018.
The DCH study is an ongoing Danish cohort study 
designed to investigate the relation between diet, lifestyle 
and disease risk.63 The cohort consists of 57 053 persons, 
recruited between December 1993 and May 1997. All the 
subjects (50–64 years of age) gave detailed information 
on diet (Food Frequency Questionnaire [FFQ]) and 
other lifestyle data. Questionnaire data on diet and life-
style were collected at study entry.63 Data from the DCH 
cohort will be combined with Danish health registries 
(the National Patient Registry [NPR], the Danish Civil 
Registration System [CRS], The Danish National Prescrip-
tion Registry [DNPR] and the Danish Multiple Sclerosis 
Registry [DMSR]).
Participant characteristics and eligibility criteria
Criteria for inclusion: the population to be studied include 
participants in the DCH cohort.63 In short, the criteria for 
invitation to the DCH cohort were: age between 50 and 
64, born in Denmark, and no diagnosis of cancer regis-
tered in the Danish Cancer Registry. All persons fulfilling 
these criteria and living in the areas of Copenhagen and 
Aarhus were invited.63
Criteria for exclusion: participants registered in NPR or 
DMSR with a CID primary diagnosis from a department 
with relevant area of specialisation in the period between 
1977 and entry to the DCH cohort will be excluded 
regardless of whether the person receive medical treat-
ment for CID or not.
the danish health registries
We will extract data from the four national registries in 
those time periods that is possible for each registry: NPR 
from 1977 to 2018, CRS from 1977 to 2018, DNPR from 
1994 to 2018 and DMSR from 1977 to 2018. An overview 
of the information obtained from the different registries 
is presented in table 1.
The NPR will be used to identify patients with CID 
during follow-up and, in addition, patients with CID 
before study entry. The NPR contains data on all patients 
admitted to Danish hospitals since 1977. The register 
covers both inpatient and outpatient records and indi-
cates the main medical reason for diagnostic procedures 
Table 1 Overview of registry information
Variable Definition Registry Time period
CPR Civil Registration Number CRS 1977–2018
ICD-10 code* International Classification of Diseases NPR 1994–2018
ICD-8 code* International Classification of Diseases NPR 1977–1993
Medication (ATC code) Anatomical Therapeutic Chemical classification 
(ATC) code
DNPR 1994–2018
Treatment code Medical treatment classification code NPR 1994–2018
Department with relevant area of 
specialisation
Medical and gastroenterological department 
(IBD), medical and rheumatological department 
(RA, PsA), Medical and dermatological 
department (PsA, PsO)
NPR 1977–2018
ICD-8 and ICD-10 codes for multiple 
sclerosis (MS)
Diagnostic codes for MS DMSR 1977–2018
*ICD-8 and ICD-10 codes in the period 1977–1997 will be used to define chronic inflammatory disease diagnosis.
CRS, The Danish Civil Registration System; DMSR, Danish Multiple Sclerosis Registry; DNPR, Danish National Prescription Registry; 
IBD, inflammatory bowel disease; NPR, National Patient Registry; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.
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or treatment (since 1971 according to the eight version 
and 1994 according to the tenth version of the Interna-
tional Classification of Diseases [ICD-8 and ICD-10]). 
ICD-8 and ICD-10 codes will be used to identify cases diag-
nosed before entry to the DCH cohort study. Information 
on the departments with the relevant areas of specialisa-
tion will be obtained from the NPR and used to identify 
cases as described in the Data analysis section.
The DMSR will be used to identify patients with MS 
during follow-up, and in addition, patients with MS 
before study entry.
The DNPR will be used to obtain information on the 
medical treatment according to the Anatomical Thera-
peutic Chemical classification (ATC) code.
From the CRS, we will extract follow-up information on 
civil status, death and immigration.
Data will be linked by the unique identification number 
assigned to all residents in Denmark at birth or first 
immigration which provides a unique opportunity to link 
information about diagnoses, medications, etc., at the 
individual level.
outcome and exposures
Outcome: in this study, the outcome late-onset CID is 
defined as one of the following diseases: CD, UC, PsO, 
PsA, RA or MS. This outcome is defined by fulfilling the 
following two criteria: (1) having the CID disease in NPR 
(except MS) from a department with relevant area of 
specialisation, or in the DMSR (MS) during the follow-up 
period and (2) being treated (irrespective of the number 
of treatments) with a drug used for the specific disease, 
and the treatment being registered either in the DNPR 
or from a department with relevant area of specialisation 
(criterion 2 will not apply to MS). The outcome late-onset 
CIDs with the associated ICD-8 and ICD-10 codes and the 
ATC codes in DNPR and treatment codes in the NPR are 
specified in table 2. The date and year of the diagnosis 
are defined as the date and year of the diagnosis in NPR 
Table 2 Specification of outcome chronic inflammatory diseases (CIDs) with associated diagnostic code and treatment codes
CID
Diagnostic code (NPR)
Medical treatment (DNPR and 
NPR) Department with 
relevant area of 
specialisationICD-8* ICD-10
ATC code 
(DNPR)†
Treatment code 
(NPR)†
Crohn’s disease (CD) 563.00, 563.02, 
563.08,
563.09,
563.91
K50.0–50.9 L04AB02
L04AB04
L04AB06
L04AB05
L04AA33
L04A×01
L04A×03
L01BB02
A07E
BOHJ18A1
BOHJ18A3
BOHJ18A4
BOHJ18A5
BOHJ26
BOHJ19H4
Gastroenterology,
internal medicine
Ulcerative colitis (UC) 563.99, 563.19
569.04
K51.0–51.9 Gastroenterology,
internal medicine
Chronic polyarthritis, 
including RA
712.19, 712.29, 
712.39, 712.59
M05.9, M06.0 L04A×01
L04A×03
L04AA13
P01BA02
BWHA115
BLHM2
BWHB83
BOHJ18
Rheumatology, internal 
medicine
Psoriatic arthritis 696.09 M09.0, M07.3, 
M46.8+M07.2
Rheumatology,
internal medicine
Psoriasis 696.10, 696.19 L40.0–40.9 D05A×02
D05BB02
D05B
L04AA32
L04AB01-02
L04AB04
L04AC05
L04AC10
L04AC13
L04AD01
L04A×03
BWHA115
BOHJ20
BNHC
BOHJ18A1-3
BOHJ18B3
BOHJ18B5
Dermatology,
internal medicine
Multiple sclerosis (MS) 734.0–9‡ G35.9‡ Not used Not used Danish Multiple 
Sclerosis 
Registry (DMSR)
*International Classification of Disease (ICD)-8 and ICD-10 codes will be used to define participants with a CID diagnosis.
†These Anatomical Therapeutic Chemical classification (ATC) and treatment codes for CD and UC are used by the Danish National Registry 
for Biological Therapy in Inflammatory Bowel Disease.98
‡ICD-8 and ICD-10 codes for MS will be extracted from the DMSR.
DNPR, Danish National Prescription Registry; NPR, National Patient Registry; RA, rheumatoid arthritis.
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and/or DMSR. If a patient has several CID diseases, only 
time to the first diagnosis will be included in the analyses.
Exposure and possible confounders: information on 
exposure in this study is defined as high-fibre intake and 
high red meat, and processed meat intake, and also other 
dietary and lifestyle factors.
In the DCH study, information on diet and lifestyle 
exposure was collected at enrolment using questionnaires 
as has been described in detail elsewhere.63 In short, in 
the FFQ diet consumption was assessed in 12 categories 
of predefined responses, ranking from ‘never’ to ‘eight 
times or more per day over the past 12 months’. The daily 
intake was then calculated by FoodCalc.63 Both intake 
of dietary fibre and red meat and processed meat were 
measured as continues variable in g/day. The initially 
collected data on diet and lifestyle exposure of the DCH 
cohort is used as the baseline information on exposure 
in this study.
Information on dietary and lifestyle exposures used 
for this study is specified in table 3. Fibres, red meat and 
processed meat are defined based on the classification 
of the food items in the DCH study,63 and with inspira-
tion from other studies using dietary data from the DCH 
cohort.64–66 Red meat is defined as fresh and minced 
meat (unprocessed) from beef, veal, pork and lamb 
and excluding poultry, fish and eggs. Processed meat 
consists of red meat, poultry and fish items that have 
undergone processing such as smoking, salting or curing. 
This includes various kinds of sausages, salami, smoked 
or cooked ham, poultry or fish, other cold cuts, bacon 
and liver pate. Poultry includes chicken and turkey both 
unprocessed and processed, such as various cold cuts of 
chicken and turkey. Fish includes all unprocessed and 
processed fish as well as shellfish. Total meat is defined as 
the total of red (unprocessed) meat, red processed meat 
together with poultry and fish.64–66 Fibres are defined as 
fibres from fibrous food items from the FFQ.
Information on possible confounders will also be 
obtained from the questionnaire data at enrolment in 
relation to sex, age, education after basic school, BMI, 
physical activity, energy, HRT, comorbidity, smoking 
status, alcohol intake and also intake of fermented dairy 
products. The Charlsons Comorbidity Index67 will be 
used to classify comorbidity among the study participants. 
ICD-8 and ICD-10 codes from the NPR will be used to 
calculate the Charlson score, using the updated Charlson 
Comorbidity Index.68
Primary exposure variable: the primary exposure vari-
ables will be analysed in tertiles. Based on the hypothesis 
that the risk of CID and late-onset CID will be lower among 
those with a high fibre/low red meat, and processed meat 
intake compared to those with a low fibre/high red meat, 
and processed meat intake, it is expected that
 ► The upper tertile of the sample (33.3% of the total 
sample), based on the ratio of fibre/meat intake, is 
associated with lower risk of CID and late-onset CID.
 ► The lower tertile of the sample (33.3% of the total 
sample) with respect to intake of red meat and 
processed meat and the upper tertile of the sample 
(33.3% of the total sample) with respect to intake of 
dietary fibres are independently associated with lower 
risk of CID and late-onset CID, and a potential inter-
action between them may further lower the risk of 
CID and late-onset CID.
Other (exploratory) exposure variables:
 ► Other dietary and lifestyle factors independently 
or combined will be analysed, and are presented in 
table 3.
statistical analysis plan
The data obtained from this study will be used to inves-
tigate our ability to predict risk of late-onset CID, based 
on whether a diet high in fibre and low in red meat, and 
Table 3 Specification of exposures and overall food groups 
and lifestyle factors
Variable Definition (unit)
Diet
  Total energy intake kJ/day
  Total meat g/day
   Red meat g/day
   Red, processed meat g/day
   Fish (fresh and processed) g/day
   Poultry (fresh and processed) g/day
  Total dietary fibre intake g/day
   Legumes g/day
   Vegetables g/day
   Fruits g/day
   Cereals g/day
  Dairy products g/day
Lifestyle factors
  Alcohol intake Units of alcohol/week*
  Smoking status Yes/no
   Former smoker
   Current smoker
   Never smoker
  Metabolic equivalent of task (MET) 
score (physical activity)
hours/week
  Body mass index kg/cm2
  Highest education after basic 
school
Yes/no
   Vocational education
   Higher education 1–2 years
   Higher education 3–4 years
   Higher education >4 years
  Comorbidity (Charlson 
Comorbidity Index)
Index score
  Hormone replacement therapy Yes/no
*One unit of alcohol is defined as 12 g of pure alcohol.
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processed meat is a predictive factor. Furthermore, data 
on other lifestyle factors and dietary factors obtained 
from the FFQ will be used to investigate whether these 
factors potentially could give rise to confounding of the 
association between fibre/meat intake and risk of late-
onset CID.
Descriptive analyses for categorical variables will be 
presented as frequencies, and differences between late-
onset CID cases and non-cases will be evaluated by χ2 test. 
Continuous variables will be tabulated as medians (with 
quartiles, Q1 and Q3) and non-parametric tests on the 
equality of medians will be used to test for differences 
between groups. P values below 0.05 will be considered 
statistically significant. Negative binomial regression will 
be applied to calculate incidence rates per 1000 patient 
years and incidence rate ratios between exposures. To 
investigate the risk of and time to CID diagnosis, the Fine-
Gray competing risk regression model will be applied, and 
thus competing risk of death will be taken into account 
while handling emigration as censoring and reporting 
cumulative incidences and sub-HRs and the corre-
sponding p values for late-onset CID associated with spec-
ified food substitutions. Regressions will be carried out as 
both crude regressions, only including the exposure, and 
adjusted for age, sex, lifestyle factors and selected comor-
bidities. Sensitivity analyses of the outcome variable and 
use of medication will be carried out.
Logistic regression will be conducted to examining 
the association between fibre/meat intake and already 
being diagnosed with a CID diagnose. Analyses will be 
conducted using Stata V.15.69
If power of each of the disease groups allows, there will 
be conducted subanalyses on each of the late-onset CID 
diagnoses separately with the overall aim of testing if the 
hypothesised association between diet factors and devel-
opment of late-onset CID is applicable for all the late-
onset CIDs or if some of the late-onset CIDs deviate from 
this association. Moreover, analyses omitting MS from the 
overall definition of CID will be performed.
Information on the departments with the relevant areas 
of specialisation will be used to evaluate the robustness 
of the diagnosis codes from the NPR and to identify the 
cases as we will only accept cases that have a diagnosis 
from a relevant department. The DMSR is highly vali-
dated,70 and data from the registry will be used to ensure 
complete follow-up of valid diagnoses of MS.
Power considerations, late-onset CID: the age-adjusted 
(age between 45 and 69) incidences per 100 000 years of 
the CIDs in Denmark are 10.1–10.6 for CD71; 27.5–32.7 
for UC71; 200–225 for PsO15; 28–35 for PsA16; 4.4–7.5 
for MS19 72–75 and 28.1–57.6 for RA.76 77 In the cohort of 
approximately 57 000 participants and a follow-up period 
of approximately 20 years, these incidences correspond 
to an estimate of approximately 2000 cases of CID in the 
cohort. To estimate the power of the study, we therefore 
expect approximately 2000 cases of CID, that is, an inci-
dence of about 3% and about one-third of the cohort 
in the low risk and two-thirds in the high-risk exposure. 
Assuming a fixed follow-up of 20 years and a relevant effect 
size of 2% CID risk in the low-risk exposure compared 
with 3% in the high-risk exposure, this would require 
11 667 participants to obtain a power of 0.90 in an (unad-
justed) χ2 test. Hence, with a total cohort size of approxi-
mately 57 000, this should ensure a sufficient power even 
when taking loss to emigration and competing risk of 
death (resulting in less than 20-year follow-up for some 
participants) into account.
Patient and public involvement
This study is register based and there will be no patients 
or public involvement in the study.
strengths and limitations of the study
A strength of this study is that it is not limited to one 
disease, as it includes several CIDs. Another strength is 
that the linkage to Danish health registries will ensure 
almost complete follow-up of the study population, as the 
Danish health registries are considered the internation-
ally most comprehensive with high validity.78–81 Further-
more, in this study, we have chosen very restrictive criteria 
for defining the late-onset CID cases by requiring that 
cases fulfil both diagnostic and treatment criteria, or that 
the cases were registered in the DMSR. This approach 
ensures that a high proportion of the identified cases 
really had late-onset CID. Therefore, some ‘real’ CID 
cases might not have been identified, hence lowering the 
sensitivity.70 82 83
A possible limitation of this study could have been the 
validity of the diagnostic codes from the NPR and the 
treatment codes from the DNPR as criteria for identifying 
late-onset CID cases.70 82 But, as described in the analysis 
plan, this potential limitation will be sought eliminated by 
using the information on the hospital departments, and 
for MS, using the DMSR for identifying MS cases. In addi-
tion, usually dietary habits do not change much during 
life. Therefore, the exposure time to the diet is long in 
50+age group and a possible impact of diet is possibly 
located much earlier in life. Therefore, we have included 
an analysis among those who at entry to the DCH cohort 
already had a CID diagnosis to examine if their low/high 
intake of dietary fibre, red meat and processed meat is 
associated with having CID. We are well aware that such 
an analysis might be impacted by bias by indication and 
that the results should be interpreted with this in mind.
The FFQ applied in the present study has been used 
in the large, European prospective cohort study ‘The 
European Prospective Investigation into Cancer and 
Nutrition’ (EPIC),84 85 and it has been used and evaluated 
in the Danish population, with results that demonstrate 
consistency.86–88 However, the FFQ is not without limita-
tions, with respect to the lack of information on portion 
sizes89 90 or to underestimation and overestimation of 
intake of unhealthy and healthy food.91 Any imprecision 
of the FFQ due to standardised portion sizes or incorrect 
reporting of food intake, will lead to large CIs, which 
potentially can lead to null results.8 On the other hand, 
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studies suggest that specification of a standard portion 
size may not introduce a large error in the estimation of 
food and nutrient intake.92 Furthermore, the FFQ has 
been validated as being appropriate for use in studies that 
examine relationships between diet and risk of disease.91
Another limitation of this study is the validity of the 
information on exposure as this information is collected 
at study entry, which potentially can be several years 
before any outcome appears, and measurement error in 
the FFQ may occur if the participants change their diet 
over time. Furthermore, there is a potential risk of recall 
bias according to the information on exposure, as this 
information relies on the participants’ ability to recall 
their dietary intake. In this study, however, it is expected 
that dietary and lifestyle patterns among adults are rela-
tively stable over time, based on other longitudinal studies 
that showed minimal temporal changes.93 94
The MET score is an accepted standard measure of phys-
ical activity.95 However, the weaknesses of the MET score 
include a risk of adding random variation by applying an 
assumed intensity to include activities. Another weakness 
of the MET score is the implicit assumption that the inten-
sity aspect of physical activity is important for the develop-
ment of disease.95
The study population in this study is based on a cohort 
of middle-aged women and men living in urban areas. 
This could reduce the generalisability of study findings, 
as the incidence of CID diagnoses could be different for 
younger persons and persons from rural areas.
The disease groups may be heterogeneous regarding 
dietary and lifestyle factors. This study may not capture 
every dietary and lifestyle difference between the disease 
groups, due to insufficient power of each disease group, 
as described in the analysis plan. Replication of the 
results in other well-characterised populations using 
prospectively sampled dietary data will minimise the risk 
of potential type 2 errors. Study results should preferably 
be replicated in cohorts in other countries and other age 
groups for further evaluation of the robustness of the 
results.
Project organisation
This registry study is a cross-disciplinary collaboration 
that includes clinical specialists within neurology, derma-
tology, rheumatology, IBDs, prospective cohort study 
design and clinical registries.
Perspectives
We anticipate that the PROCID-DCH study will reveal 
factors of importance, including whether the diet is likely 
to interfere with the disease risk of late-onset CID.
The perspective is that significant results from this study 
will be sought replicated in other cohorts such as the 
EPIC-IBD84 and UK biobank96 with high-quality prospec-
tive lifestyle data. Successful replication indicates the 
robustness of the findings which is an important step on 
the road to developing clinical tools for effective person-
alised prevention of individuals at high risk.
dissemination of results to the public and scientifically
Target journals include international journals within 
internal medicine. In addition to the scientific reporting 
of results, major findings with translational implications 
will also be communicated to categories of both health 
professionals, and targeted stakeholders including public 
health policy-makers, and to the general public through 
various media and news activities. Intellectual Property 
Rights to discoveries based on the outlined research 
belong to the University of Southern Denmark.
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